VTR-297 is under clinical development by Vanda Pharmaceuticals and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to GlobalData, Phase I drugs for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VTR-297’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VTR-297 is under development for the treatment of relapsed and/or refractory haematological malignancies, multiple myeloma, non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. It is administered through Intravenous infusion. It is a natural derivative of dienohydroxamic acid isolated from species of the bacterial genus Streptomyces. It acts by targeting histone deacetylase.
Vanda Pharmaceuticals overview
Vanda Pharmaceuticals (Vanda) a biopharmaceutical company that develops and commercializes novel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a typical antipsychotic for the treatment of schizophrenia in adults. Its major pipeline products include Tradipitant (VLY-686), VTR-297, VQW-765, CFTR and portfolio of cystic fibrosis transmembrane conductance regulator inhibitors and activators. Vanda is headquartered in Washington, Washington DC, the US.
For a complete picture of VTR-297’s drug-specific PTSR and LoA scores, buy the report here.